This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study Evaluating Vardenafil Compared to Placebo in Subjects With Erectile Dysfunction (ED) and Dyslipidemia

This study has been completed.
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: September 21, 2006
Last updated: June 7, 2012
Last verified: March 2011
This is a study consisting of four periods (screening, run-in, treatment, follow-up). A four-week treatment-free, run-in period where the subject will make at least four attempts at intercourse on four separate days with at least 50% of the attempts must be unsuccessful. During run-in the subjects will be using a stopwatch to measure the time from erection perceived hard enough for penetration until withdrawal from the partner's vagina. Next there are 12 weeks of treatment with either placebo or LEVITRA. Each subject will be required to visit the clinic on 5 occasions over a period of 4 months.

Condition Intervention Phase
Erectile Dysfunction (ED) Erectile Dysfunction Drug: LEVITRA (vardenafil) Drug: placebo Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Study Evaluating the Efficacy, Safety, and Duration of Erection of Flexible-dose Vardenafil Administered for 12 Weeks Compared to Placebo in Subjects With Erectile Dysfunction and Dyslipidemia

Resource links provided by NLM:

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • EF domain score of the International Index of Erectile Function (IIEF) at randomization and every 4 weeks during therapyDiary response: success of insertion and maintenance recorded at every attempt from randomization through end of treatment [ Time Frame: 12 week study ]

Secondary Outcome Measures:
  • Duration of erection and specific diary responses concerning satisfaction: every attemptResponse to diary questions and scores for Keep It Simple (KIS): randomization and every 4 weeksResponse to Global Assessment Question (GAQ): every 4 weeks [ Time Frame: 12 week study ]

Enrollment: 510
Study Start Date: May 2006
Study Completion Date: May 2007
Primary Completion Date: May 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Levitra
10mg x 4 weeks, with option to increase to 20mg aat that time if desired
Drug: LEVITRA (vardenafil)
active comparator
Placebo Comparator: placebo Drug: placebo
placebo comparator


Ages Eligible for Study:   18 Years to 64 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Males with ED for more than six months, according to the NIH Consensus Statement (inability to attain and/or maintain penile erection sufficient for satisfactory sexual performance).
  • Stable heterosexual relationship for more than 6 months.
  • The subject must make at least four attempts at sexual intercourse (according to the question in the subject diary: Was sexual activity initiated with the intention of intercourse?) on four separate days during the untreated baseline period. At least 50% of attempts during this period must be unsuccessful, according to the following questions from the subject diary [at least one question should be answered "No"]: Were you able to achieve at least some erection (some enlargement of the penis)? Were you able to insert your penis into your partner's vagina? Did your erection last long enough for you to have successful intercourse?
  • Diagnosis of dyslipidemia treated with a stable dose of a statin for 6 months at Visit 1.
  • IIEF-EF domain score of 25 denoting mild to severe ED at Visit 2.
  • Documented, dated, written Informed Consent.

Exclusion criteria:

  • Premature ejaculator <2 minutes
  • Any unstable medical, psychiatric, spinal cord injury, penile anatomical abnormalities, or substance abuse disorder that MD feels subject will not be able to complete the study.
  • Low sexual desire.
  • Prior prostatectomy surgery
  • Severe chronic or acute liver disease, history of moderate or severe liver impairment
  • Clinically significant chronic hematological disease
  • Bleeding disorder or significant active peptic ulceration.
  • Cardiovascular conditions that prevent sexual activity.
  • History of heart attack, stroke, or life-threatening arrhythmia within the prior 6 months.
  • hypotension or hypertension at rest.
  • cancer within the past 5 years. Use of these medications: nitrates or nitric oxide donors, anti-androgens, oral or injectable androgens, received any investigational drug (including placebo) within 30 days of screening (Visit 1).
  • Use of any treatment for ED within 7 days of screening including oral medications, vacuum devices, constrictive devices, injections or urethral suppositories.
  • Subjects who are taking the following potent inhibitors of cytochrome P-450 3A4.
  • Abnormal Laboratory Values:

    1. serum total testosterone level >25% below the lower limit of normal
    2. serum creatinine >3.0 mg/dl.
    3. AST and/or ALT >3x the upper limit of normal.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00379756

  Hide Study Locations
United States, Alabama
GSK Investigational Site
Fairhope, Alabama, United States, 36532
GSK Investigational Site
Homewood, Alabama, United States, 35209
GSK Investigational Site
Huntsville, Alabama, United States, 35801
United States, Arizona
GSK Investigational Site
Phoenix, Arizona, United States, 85016
GSK Investigational Site
Phoenix, Arizona, United States, 85023
United States, California
GSK Investigational Site
Concord, California, United States, 94520
GSK Investigational Site
Huntington Park, California, United States, 90255
GSK Investigational Site
Newport Beach, California, United States, 92660
GSK Investigational Site
Orangevale, California, United States, 95662
GSK Investigational Site
Santa Ana, California, United States, 92705
GSK Investigational Site
Walnut Creek, California, United States, 94598
United States, Colorado
GSK Investigational Site
Denver, Colorado, United States, 80210
GSK Investigational Site
Wheat Ridge, Colorado, United States, 80033
United States, Connecticut
GSK Investigational Site
New Britain, Connecticut, United States, 06052
United States, Florida
GSK Investigational Site
Aventura, Florida, United States, 33180
GSK Investigational Site
Clearwater, Florida, United States, 33761
GSK Investigational Site
Coral Gables, Florida, United States, 33134
GSK Investigational Site
Fort Myers, Florida, United States, 33916
GSK Investigational Site
North Miami, Florida, United States, 33161
GSK Investigational Site
Pembroke Pines, Florida, United States, 33024
GSK Investigational Site
Pinecrest, Florida, United States, 33156
GSK Investigational Site
Sarasota, Florida, United States, 34237
GSK Investigational Site
South Miami, Florida, United States, 33143
GSK Investigational Site
St. Petersburg, Florida, United States, 33710
GSK Investigational Site
West Palm Beach, Florida, United States, 33401
United States, Georgia
GSK Investigational Site
Atlanta, Georgia, United States, 30342
GSK Investigational Site
Dawsonville, Georgia, United States, 30534
GSK Investigational Site
Roswell, Georgia, United States, 30076
GSK Investigational Site
Woodstock, Georgia, United States, 30189
United States, Indiana
GSK Investigational Site
Avon, Indiana, United States, 46123
GSK Investigational Site
Evansville, Indiana, United States, 47714
GSK Investigational Site
Fort Wayne, Indiana, United States, 46825
GSK Investigational Site
Jeffersonville, Indiana, United States, 47130
United States, Kansas
GSK Investigational Site
Wichita, Kansas, United States, 67207
United States, Kentucky
GSK Investigational Site
Lexington, Kentucky, United States, 40509
GSK Investigational Site
Madisonville, Kentucky, United States, 42431
United States, Louisiana
GSK Investigational Site
Shreveport, Louisiana, United States, 71106
United States, Maine
GSK Investigational Site
Swansea, Maine, United States, 02777
United States, Massachusetts
GSK Investigational Site
Taunton, Massachusetts, United States, 02780
United States, Michigan
GSK Investigational Site
Kalamazoo, Michigan, United States, 49009
United States, Minnesota
GSK Investigational Site
St. Louis Park, Minnesota, United States, 55416
United States, Missouri
GSK Investigational Site
St. Louis, Missouri, United States, 63117
United States, Nebraska
GSK Investigational Site
Omaha, Nebraska, United States, 68134
United States, Nevada
GSK Investigational Site
Las Vegas, Nevada, United States, 89119
United States, New Jersey
GSK Investigational Site
Lawrenceville, New Jersey, United States, 08648
United States, New York
GSK Investigational Site
Rochester, New York, United States, 14609
United States, North Carolina
GSK Investigational Site
Charlotte, North Carolina, United States, 28262
GSK Investigational Site
Fayetteville, North Carolina, United States, 28304
GSK Investigational Site
Winston-Salem, North Carolina, United States, 27103
United States, Pennsylvania
GSK Investigational Site
Shippensburg, Pennsylvania, United States, 17257
United States, Tennessee
GSK Investigational Site
Nashville, Tennessee, United States, 37203
United States, Texas
GSK Investigational Site
Amarillo, Texas, United States, 79106
United States, Utah
GSK Investigational Site
Salt Lake City, Utah, United States, 84107
United States, Virginia
GSK Investigational Site
Norfolk, Virginia, United States, 23502
GSK Investigational Site
Richmond, Virginia, United States, 23294
United States, Wisconsin
GSK Investigational Site
Menomonee Falls, Wisconsin, United States, 53051
GSK Investigational Site
Milwaukee, Wisconsin, United States, 53209
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Responsible Party: GlaxoSmithKline Identifier: NCT00379756     History of Changes
Other Study ID Numbers: 106718
Study First Received: September 21, 2006
Last Updated: June 7, 2012

Keywords provided by GlaxoSmithKline:
Erectile dysfunction, impotence

Additional relevant MeSH terms:
Erectile Dysfunction
Sexual Dysfunction, Physiological
Genital Diseases, Male
Sexual Dysfunctions, Psychological
Mental Disorders
Lipid Metabolism Disorders
Metabolic Diseases
Vardenafil Dihydrochloride
Vasodilator Agents
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Urological Agents processed this record on June 26, 2017